• Explore /
  • Poster
  • / Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).

Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).

Abstract Poster

Authors

null

Xiaofeng Chen

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;

Xiaofeng Chen , Hao Xu , Deqiang Wang , Xiaobing Chen , Kangxin Wang , Guangfu Jin , Yongbin Ding , Jie Tang , Yueyu Fang , Hui Sun , Qiusheng Jiang , Lanlan Pan , Yitong Tian , Rong Wang , Tongpeng Xu , Lijuan Meng , Fengyuan Li , Yongqian Shu , Fen Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

ChiCTR2000034109

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 365)

DOI

10.1200/JCO.2023.41.4_suppl.365

Abstract #

365

Poster Bd #

F6

Abstract Disclosures

Similar Posters

First Author: Yakun Wang

First Author: Jie Shen

First Author: Lin Shen

First Author: MinKe He